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Aim: Based on the ability of apoptosis to induce immunological tolerance, liposomes 
were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 
diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: 
multiple sclerosis. Materials & methods: Phosphatidylserine-rich liposomes were 
loaded with disease-specific autoantigen. Therapeutic capability of liposomes was 
assessed in vitro and in vivo. Results: Liposomes induced a tolerogenic phenotype in 
dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying 
the onset and reducing the severity of experimental disease, correlating with an 
increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. Conclusion: This is 
the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest 
multiple sclerosis, demonstrating its relevance for clinical application.
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Liposomes are small vesicles with an aqueous 
core encapsulated by a lipid bilayer that con-
stitute a promising drug delivery system [1]. 
Liposome formulations have progressed and 
they are still improving [2,3], and currently 
they represent an innovative area of great 
scientific interest due to their wide variety of 
potential applications in biomedicine. Lipo-
somes protect encapsulated molecules against 
degradation and can be designed to deliver 
them into specific target cells [4]. Various 
types of liposomes are used clinically as vehi-
cles for drugs and vaccines [5]. Liposomes can 
be designed for multiple purposes, including 
immune modulation to enhance or inhibit a 
specific response [6].
We recently developed a liposome-based 
immunotherapy – inspired by the features of 
apoptotic cells [7] – to re-establish tolerance 
to self and avoid autoimmune diseases [8]. 
These liposomes are rich in phosphatidyl-
serine (PS), a phospholipid membrane com-
ponent that is exposed in apoptotic cells and 
modulates immune responses [9], and are 
loaded with self-peptides – named autoanti-
gens – as the selective molecule for tolerance 
induction. PS is recognized by membrane 
receptors of antigen presenting cells – mainly 
dendritic cells (DCs) – acting as an ‘eat me’ 
and ‘tolerate me’ signal, which allows the 
encapsulated autoantigen to be presented in 
a tolerogenic manner. Working synergisti-
cally, PS-liposomes and encapsulated autoan-
tigens display a big translational potential in 
pathologies that require the re-establishment 
of immune tolerance.
Autoimmune diseases are caused by the 
selective destruction of the host’s own cells 
by autoreactive T lymphocytes that recog-
nize autoantigens. There are nearly 100 auto-
immune diseases, affecting around 3–5% 
of the population [10]. There is no cure for 
any of them and their etiology is unknown. 
Moreover, incidence is increasing in the last 
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years [11]. The current therapies for autoimmune dis-
eases are not enough effective and cause side effects, 
such as immunosuppression. Therefore, antigen-spe-
cific, simple and safe approaches to recover self-toler-
ance are required to arrest autoimmunity and to allow 
target tissue regeneration. In our previous study, an 
innovative liposome-based immunotherapy – mimick-
ing apoptotic β cells to induce self-tolerance – arrested 
autoimmunity in Type 1 diabetes (T1D) [8]. Consider-
ing the potential of liposomes as immunomodulators, 
we aimed to develop PS-liposomes for another auto-
immune disease, multiple sclerosis (MS), to validate 
their tolerogenic power.
MS is a chronic autoimmune disease of the CNS 
in which several myelin peptides become the tar-
get autoantigens of autoreactive T cells [12]. Genetic 
and environmental factors contribute to the etiology 
of the disease but the triggering factor is not known. 
The autoimmune attack involves autoreactive T and 
B cells [13]. Eighty percent of individuals with MS ini-
tially develop a clinical pattern with periodic relapses 
followed by partial or full remission of the symptoms, 
called relapsing-remitting MS [14]. This disease is 
characterized by widespread inflammation, multifocal 
demyelination and axonal loss. The current treatments 
are systemic immunointerventions, with important 
side effects [15]. In this context, PS-liposomes loaded 
with an autoantigen of the disease, the myelin-oligo-
dendrocyte glycoprotein peptide 40–55 (MOG
40–55
), 
have been proved as a potential antigen-specific 
 therapy for MS patients.
For this purpose, we evaluated the in vivo efficacy 
of antigen-loaded PS-liposomes in the animal model 
of MS, the experimental autoimmune encephalomy-
elitis (EAE). EAE is an immune-mediated disease 
that reproduces the main clinical and histopathologi-
cal characteristics of the human disease. It is induced 
by the administration of myelin antigens. The most 
frequent EAE model used is C57BL/6 mice injected 
with the MOG
40–55
 peptide [16,17], and it has been the 
major tool to understand the mechanism involved in 
MS pathogenesis, as well as to test therapies for the 
human disease. To determine the effect of a therapy 
in EAE, three different approaches can be used: pre-
ventive (before immunization), preclinical (postim-
munization) and therapeutic (after the onset of the 
disease) [17]. Using EAE preclinical approach, we 
report here the beneficial effect of liposomes rich in 
PS and loaded with MOG peptide. This work dem-
onstrates that a simple apoptosis-based strategy has 
the inherent potential of stopping an ongoing auto-
immune reaction such as the EAE, validating the 
immunotherapy and confirming its potential to arrest 
autoimmunity.
Materials & methods
Mice
Wild-type C57BL/6 inbred mice were purchased from 
Envigo Rms Spain SL (Sant Feliu de Codines, Barce-
lona, Spain) and housed at the Animal House facility at 
the Germans Trias i Pujol Research Institute. Mice were 
maintained under conventional conditions in a temper-
ature and humidity-controlled room with 12-h light/12-
h dark cycle, with standard chow diet (Teklad Global 
14% Protein Rodent Diet, Envigo) and water provided 
ad libitum. Only females were used in this study.
Liposomes & peptides
MOG
40–55
 peptide (YRSPFSRVVHLYRNGK, Immu-
nostep, Salamanca, Spain), >95% pure, was chosen 
because it is a target epitope in MS patients [18]. Lipo-
somes were composed of 1,2-dioleoyl-sn-glycero-
3-phospho-L-serine (sodium salt) (DOPS, Lipoid, 
Steinhausen, Switzerland) and 1,2-didodecanoyl-sn-
glycero-3-phosphocholine (DLPC, Lipoid), and choles-
terol (CH, Sigma Aldrich, MO, USA). Liposomes were 
prepared using the thin film hydration method from 
a lipid mixture of DOPS, DLPC and CH at 1:1:1.33 
molar ratio, respectively, as described [19], under sterile 
conditions and at a final concentration of 30 mM. Lip-
ids were dissolved in chloroform and the solvent was 
removed by evaporation under vacuum and nitrogen. 
The lipids were hydrated with the appropriate buffer 
(phosphate-buffered saline [PBS], 0.5 mg/ml solution 
of MOG
40–55
 peptide) and the liposomes obtained were 
homogenized to 1 μm by means of an extruder (Lipex 
Biomembranes, Vancouver, Canada). Encapsulation 
efficiencies (EE) were calculated according to the equa-
tion EE (%) = [(C
peptide, total
-C
peptide, out
)/C
peptide, total
] × 100, 
where C
peptide, total
 is the initial MOG
40–55
 peptide con-
centration and C
peptide, out
 is the concentration of nonen-
capsulated peptide. To measure the C
peptide, out
, liposome 
suspensions were centrifuged at 110,000 × g for 30 min 
at 10°C. The concentration of nonencapsulated peptide 
was assessed in supernatants by PIERCE BCA protein 
assay kit (Thermo Fisher Scientific Inc., IL, USA). 
In addition to PS-rich liposomes loaded with MOG 
(PSMOG-liposomes), empty liposomes were generated 
as controls (PS-liposomes). Particle size distribution and 
stability – expressed as ζ potential – were measured by 
dynamic light scattering using Malvern Zetasizer (Mal-
vern Instruments, Malvern, UK) in undiluted samples. 
Liposome morphology and lamellarity were examined 
by cryogenic transmission electron microscopy in a 
JEOL-JEM 1400 microscope (Jeol Ltd., Tokyo, Japan).
DC generation
DCs were differentiated from bone marrow progeni-
tor cells in supplemented RPMI-1640 culture medium 
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(Biowest, Nuaillé, France) containing 10% heat-inacti-
vated fetal bovine serum (Gibco, Invitrogen, CA, USA), 
100 U/ml penicillin (Normon SA, Madrid, Spain), 
100 mg/ml streptomycin (Reig Jofre, Sant Joan Despi, 
Spain), 2 mM glutamine (Sigma), 1 mM sodium pyru-
vate (Gibco), 50 μM beta-mercapto ethanol (Sigma) 
and mouse GM-CSF (1000 U/ml; Prospec, Rehovot, 
Israel), as previously reported [20]. DC purity was 
assessed by CD11c-PE-Cy7 staining (BD Biosciences, 
CA, USA) and cell viability was determined by annexin 
V-PE and 7-AAD staining (BD Biosciences) by flow 
cytometry (FACS Canto II, BD Biosciences).
Liposome capture by DCs
To determine whether liposome capture by DCs takes 
place by phagocytosis, DCs were co-cultured with 100 
μM fluorescence labeled PS-liposomes (PS-lipo-OG488; 
Oregon green 488 DHPE, Invitrogen, CA, USA) dur-
ing 5 min to 6 h at 37 and 4°C. Cells were extensively 
washed in PBS to remove all liposomes attached to the 
cell membrane. Liposome endocytosis was determined 
by flow cytometry (FACSCanto II, BD Biosciences).
Assessment of DCs phenotype after liposome 
uptake
DCs were co-cultured with 1 mM empty liposomes 
(PS-DCs), liposomes loaded with MOG peptide 
(PSMOG-DCs) or the equivalent amount of MOG 
peptide (MOG-DCs) during 24 h, and their pheno-
type was analyzed by flow cytometry (FACSCanto II, 
BD Biosciences). As controls, DCs were either cultured 
in basal conditions to obtain immature DCs (iDCs) or 
with lipopolysaccharide (100 ng/ml; Sigma) for 24 h 
to obtain mature DCs. DCs were stained with mono-
clonal antibodies to CD11c-PE-Cy7, CD40-APC, 
CD86-PE and class II major histocompatibility com-
plex (MHC) I-A/I-E-FITC (BD Biosciences). Cor-
responding fluorescence minus one staining was used 
as control. Data were analyzed using FlowJo software 
(Tree Star, OR, USA).
Prostaglandin E2 quantification
The production of prostaglandin E
2
 (PGE
2
), a potent 
immunoregulator responsible for the immunosup-
pressive mechanism of apoptotic cells, was assessed by 
ELISA (PGE
2
 EIA Kit-Monoclonal; Cayman Chemi-
cals, MI, USA), in supernatants obtained from DC 
cultures, 24 h after liposome capture. LOD: 80% 
B/B
0
: 15 pg/ml. Sensitivity: 50% B/B
0
: 50 pg/ml. 
Results were expressed as pg of PGE
2
/106 cells.
Disease induction & clinical follow-up in the 
EAE model
For the induction of EAE, C57BL/6 female mice 
(Envigo) at 8 weeks of age received subcutaneous 
injections in both flanks of 50 μg MOG
40–55
 peptide 
in PBS, emulsified in an equal volume of complete 
Freund’s adjuvant, containing 4 mg/ml of Mycobac-
terium tuberculosis H37RA (Difco, MI, USA), under 
ketamine/xylazine at 50 and 5 mg/kg body weight, 
respectively. In addition, 250 ng of Pertussis toxin 
(Sigma) were injected intravenously at day 0 and 2. All 
animals were weighed and examined daily for welfare 
and clinical signs, according to the following criteria: 
0, asymptomatic; 0.5, loss of distal half of tail tone; 
1, loss of entire tail tone; 1.5, hind limb weakness; 2, 
hind limb paralysis; 2.5, hind limb paraplegia; 3, fore-
limb weakness; 4, quadriparesis; 4.5, severe quadripa-
resis; 5, quadriplegia; and 6, death. Clinical follow-up 
analyzes were performed in a blinded manner by two 
different observers.
Treatment of EAE with liposome-based 
immunotherapy
Liposomes were administered at day 5 and 9 post 
immunization (p.i.), after EAE induction but before 
the disease onset (occurring at day 13 p.i.), to evalu-
ate the potential of the therapy in the prevention of 
EAE development. At this stage, mice did not show 
clinical signs of the disease but autoimmune destruc-
tion was ongoing. Liposomes were injected intraperi-
toneally (i.p.) at a dose of 1.75 mg of lipid in 100 μl 
of PBS. Mice were treated with liposomes filled with 
MOG peptide (PSMOG-liposomes, n = 11) and as 
controls, with empty PS-liposomes (PS-liposomes, 
n = 10), MOG peptide (MOG, n = 8) or PBS (sham, 
n = 13). Mice were pooled from two independent 
experiments.
Analysis of regulatory T cells
Regulatory T cells were assessed in the spleen of 
PSMOG-liposomes and sham-treated mice at day 15 
p.i. This checkpoint was chosen based on the time 
course of the EAE model. The MOG-specific CD4+ 
T-cell response takes 7 days approximately after EAE 
induction. Taking into account that liposomes were 
injected at days 5 and 9 post-immunization, T-cell 
analysis was performed 6 days later in order to iden-
tify the induced tolerogenic mechanisms. Splenocytes 
were obtained from mice after mechanical disruption 
and erythrocyte lysis, and analyzed by flow cytometry 
(FACSCanto II, BD Biosciences). The amount of clas-
sical CD4+ regulatory T cells (Tregs) was determined 
after membrane staining (CD3-V450, CD4-APC-Cy7; 
BD Biosciences and CD25-PE; eBioscience, CA, USA), 
fixation/permeabilization (FoxP3 fixation/permeabi-
lization Concentrate and Diluent; eBioscience) and 
intracellular staining (FoxP3-APC; eBioscience). CD4+ 
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Figure 1. Liposomes are phagocytosed by dendritic cells. (A) Cryogenic transmission electron microscopy images 
of SMOG-liposomes. Bar = 0.2 μm. (B) Time course of the capture of PS-lipo-OG488 by DCs at 37°C (white squares) 
and at 4°C (black squares). Results are mean ± SD of three independent experiments (****p < 0.0001, two-way 
ANOVA). (C) Flow cytometry contour plots of the uptake of PS-lipo-OG488 (OG488+) by DCs (CD11chigh). From left 
to right, control DCs, DCs co-cultured with PS-lipo-OG488 at 4 and 37°C. One representative experiment of three 
(30 min co-culture) is shown. Percentage of liposome capture (thick line) is referred to CD11chigh cell subset (thin 
line). 
DC: Dendritic cell; PS-lipo-OG488: OG488-labeled PS-liposome.
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type 1 T regulatory (Tr1) cells were stained with anti-
bodies to CD3-V450, CD4-APC-Cy7,  CD49b-FITC 
and  LAG-3-APC (BD Biosciences) [21].
Statistical analysis
The statistical analysis was performed using the Prism 
6.0 software (GraphPad software Inc., CA, USA). 
For comparisons of unpaired data, a nonparametric 
Mann–Whitney test was used; for paired comparisons, 
a nonparametric Wilcoxon test was used. Fisher’s exact 
test was used to compare qualitative variables. For cor-
relation between parameters, Spearman’s test was used. 
A p-value ≤0.05 was considered significant.
Results
Generation & physicochemical characterization 
of PS-liposomes loaded with MOG peptide
PS-liposomes were prepared with DOPS/DLPC/
CH at 1:1:1.33 molar ratio to present PS on their 
surface. Liposome preparations were characterized in 
terms of diameter, polydispersity index (PdI), stabil-
ity (ζ-potential) and efficiency of peptide encapsula-
Table 1. Liposome features.
Liposome type Lipid concentration 
(mM)
Diameter (nm) Polydispersity 
index (PdI)
ζ-potential (mV) Encapsulation 
efficiency (%)
PSMOG-liposomes 30.01 ± 0.06 861.29 ± 130.49 0.32 ± 0.19 -36.19 ± 5.32 91.53 ± 4.10
PS-liposomes 29.70 ± 0.46 985.33 ± 144.36 0.35 ± 0.05 -35.40 ± 8.44 −
Data presented as mean ± SD.
PSMOG: PS-rich liposome loaded with myelin-oligodendrocyte glycoprotein.
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Figure 2. Effect of the capture of phosphatidylserine-liposomes in dendritic cells phenotype. (A) DCs viability assessed by annexin 
V and 7-AAD staining. White symbols represent iDCs alone (triangles) and after the capture of MOG peptide (MOG-DCs, rhombus), 
empty PS-liposomes (PS-DCs, squares) or MOG-filled PS-liposomes (PSMOG-DCs, circles), 24 h after culture. Black symbols represent 
mDCs, after 24-h culture with LPS. Lines show the mean of six independent experiments. (B–D) MFI for MHC Class II, CD86 and CD40 
membrane expression, respectively, in DCs before and after liposome capture (white symbols) and after exposure to LPS (black 
symbols). Lines show the mean of six independent experiments. Comparisons between groups showed significant differences  
(*p < 0.05, nonparametric Wilcoxon test). 
DC: Dendritic cell; iDC: Immature DC; LPS: Lipopolysaccharide; mDC: Mature DC; MFI: Median of fluorescence intensity; MHC: Major 
histocompatibility complex; PS: Phosphatidylserine; PS-DC: DC loaded with empty PS-liposomes; PSMOG-DC: DC loaded with PS-
liposomes encapsulating MOG peptide.
iDCs PSMOG-DCs PS-DCs MOG-DCs mDCs
0
500
1000
1500
2000
2500
iDCs PSMOG-DCs PS-DCs MOG-DCs mDCs
M
F
I C
D
86
iDCs PSMOG-DCs PS-DCs MOG-DCs mDCs
0
20
40
60
80
100
V
ia
b
ili
ty
 (
%
 a
n
n
 V
- ,
7a
ad
-  o
f 
C
D
11
c+
)
0
1000
2000
3000
4000
5000
M
F
I M
H
C
 II
iDCs PSMOG-DCs PS-DCs MOG-DCs mDCs
*
0
500
1000
1500
2000
M
F
I C
D
40
*
*
*
*
*
*
future science group
Liposome-based immunotherapy for multiple sclerosis    Research Article
tion when necessary (Table 1). The final lipid concen-
tration of PSMOG-liposomes was 30.01 ± 0.06 mM 
(mean ± SD) and displayed a mean diameter of 861.29 
± 130.49 nm with a PdI of 0.32 ± 0.19. ζ-potential 
measurements revealed a net surface charge of -36.19 ± 
5.32 mV, and the mean of MOG peptide encapsulation 
efficiency was 91.53 ± 4.10%. PSMOG-liposomes pre-
sented multivesicular vesicle morphology when cryo-
genic transmission electron microscopy analysis was 
performed (Figure 1A). Empty PS-liposomes presented 
a final lipid concentration of 29.70 ± 0.46 mM, with a 
mean diameter of 985.33 ± 144.36 nm, a PdI of 0.35 ± 
0.05 and a ζ potential of -35.40 ± 8.44 mV.
PS-liposomes are efficiently phagocytosed 
by DCs
Time course analysis (Figure 1B) revealed that the 
maximum capture of PS-liposomes by DCs (81.53 ± 
2.05%, mean ± SD) was achieved after 1 h of co-cul-
ture at 37°C. OG488 fluorescence signal at 37°C was 
higher (p < 0.0001) in each checkpoint when compared 
with its counterpart at 4°C. The significantly reduced 
OG488 signal in the experiments performed at 4°C 
as well as the large diameter of the vesicles (>500 nm) 
confirms the active process of phagocytosis by which 
liposomes are captured. Figure 1C shows a representa-
tive contour plot of PS-lipo-OG488 uptake by DCs 
after 30 min of co-culture at 4 and 37°C.
PS-liposomes preserve an immature phenotype 
in DCs
To assess the tolerogenic potential of PSMOG-lipo-
somes, we analyzed their effect in DCs phenotype. 
Viability of DCs after the capture of PSMOG-lipo-
somes was always >80% (Figure 2A). Control DCs, co-
cultured with empty PS-liposomes or MOG peptide, 
behaved similarly to iDCs in terms of viability.
Afterward, the effect of liposome capture in DCs 
phenotype in terms of costimulation and antigen pre-
sentation was examined. Liposome capture did not 
affect the expression of MHC II in comparison to iDCs 
(Figure 2B). The expression of CD86 in iDCs decreased 
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Figure 3. Dendritic cells produce PGE2 after 
phagocytosis of PS-rich liposomes loaded with 
myelin-oligodendrocyte glycoprotein. Quantification 
of PGE2 released by iDCs in culture medium (triangles), 
co-cultured with PSMOG-liposomes (circles), empty PS-
liposomes (squares) or MOG peptide (rhombus) after 
24 h of culture. Data are represented as pg/106 cells. 
Lines show the mean of six independent experiments. 
Comparisons between groups showed significant 
differences (*p < 0.05, nonparametric Wilcoxon test). 
DC: Dendritic cell; iDC: Immature DC; MOG: Myelin-
oligodendrocyte glycoprotein peptide 40–55; 
PGE2: Prostaglandin E2; PS: Phosphatidylserine; 
PSMOG: PS-rich liposome loaded with myelin-
oligodendrocyte glycoprotein.
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after PSMOG-liposomes capture (p < 0.05), and the 
expression of CD40 in iDCs increased after PS- or 
PSMOG-liposomes capture (p < 0.05) (Figure 2C & D). 
The expression of CD86, CD40 and MHC class II mol-
ecules in DCs after uptake of PSMOG-liposomes was 
always significantly lower than the observed in mature 
DCs. These changes suggest that iDCs acquired a semi-
mature phenotype after capture of PSMOG-liposomes, 
a feature of tolerogenic DCs. Control DCs, co-cultured 
with empty PS-liposomes or MOG peptide, behaved 
similarly to iDCs in terms of phenotype.
Based on our previous results, PGE
2
 production by 
DCs after PS-liposomes uptake was assessed in cul-
ture supernatants. The concentration of PGE
2
 was 
significantly increased in PSMOG-DCs in compari-
son to iDCs and MOG-DCs (p < 0.05), as well as in 
PS-DCs when compared with MOG-DCs (p < 0.05) 
(Figure 3).
PS-liposomes filled with MOG peptides reduce 
EAE severity
Mice were treated with two doses of PSMOG-lipo-
somes at days 5 and 9 p.i. to prevent the development 
of EAE. As expected, all mice from the sham-control 
group (n = 13) developed EAE with a maximum score 
of 2.83 ± 1.94 (mean ± SD) (Table 2). The treatment 
with PSMOG-liposomes (n = 11) resulted in a signifi-
cant reduction of maximum disease score, this being 
of 1.41 ± 1.59, in comparison to empty PS-liposomes 
group (n = 10) (p < 0.01), whose disease score was 3.90 
± 1.70, or to MOG peptide group (n = 8), whose disease 
score was 2.38 ± 1.77. The incidence of the disease was 
lower in PSMOG-liposomes treated group (45.45%) 
in comparison to empty PS-liposomes treated (100%, 
p < 0.05) and sham group (92.31%, p < 0.05), and 
slightly lower than the MOG-treated group (75%). 
Mice treated with PSMOG-liposomes showed a lower 
cumulative EAE score (14.36 ± 17.89) than mice 
treated with empty PS-liposomes (45.60 ± 23.61) or 
sham (42.19 ± 24.99) groups (p < 0.01). Moreover, the 
onset of EAE was at day 16.00 ± 4.56 p.i. in PSMOG-
liposomes treated group, 14.80 ± 2.70 in PS-liposomes 
treated group, 15.50 ± 2.35 in MOG peptide treated 
group and 13.17 ± 4.73 in sham group. Finally, mice 
treated with PSMOG-liposomes showed a daily EAE 
score significantly lower than sham-control group and 
PS-liposomes treated group (p ≤ 0.05) (Figure 4A). In 
addition, mice treated with PSMOG-liposomes did 
not suffer a decrease in their body weight as mice from 
PS-liposomes, MOG peptide or sham groups endured 
(p < 0.001) (Figure 4B).
PSMOG-liposomes effect on T-cell subtypes
To test the effect of autoantigen-loaded PS-liposomes 
administration on regulatory T-cell subsets, intracel-
lular FoxP3 staining was carried out on splenocytes of 
sham (n = 12) and PSMOG-liposomes (n = 6) treated 
animals at day 15 p.i. Looking at CD4+ T cells, the 
treatment with PSMOG-liposomes significantly 
decreased the percentage of CD25+ FoxP3+ T cells 
when compared with sham group, that being of 10.95 
Table 2. Clinical features of experimental autoimmune encephalomyelitis in treated and control 
mice.
Treatment Sham MOG PS-liposomes PSMOG-liposomes
Incidence 12/13 (92.31%)* 6/8 (75%) 10/10 (100%)* 5/11 (45.45%)
Maximum score 2.83 ± 1.94 2.38 ± 1.77 3.90 ± 1.70** 1.41 ± 1.59
Cumulative score 42.19 ± 24.99** 25.88 ± 21.48 45.60 ± 23.61** 14.36 ± 17.89
Onset day 13.17 ± 4.73 15.50 ± 2.35 14.80 ± 2.70 16.00 ± 4.56
Data are expressed as mean ± standard deviation. Comparisons between PSMOG-liposomes treated group versus sham and PS-liposomes 
treated groups showed significant differences (*p < 0.05, Fisher’s Exact test; **p < 0.01, Mann–Whitney test).
PSMOG-liposome: PS-rich liposome loaded with myelin-oligodendrocyte glycoprotein.
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Figure 4. PS-rich liposomes loaded with myelin-oligodendrocyte glycoprotein prevent the development of experimental 
autoimmune encephalomyelitis. (A) Clinical score of experimental autoimmune encephalomyelitis performed daily for welfare and 
clinical status as well as neurological signs according to the criteria: 0, asymptomatic; 0.5, loss of distal half of tail tone; 1, loss of 
entire tail tone; 1.5, hind limb weakness; 2, hind limb paralysis; 2.5, hind limb paraplegia; 3, forelimb weakness; 4, quadriparesis; 
4.5, severe quadriparesis; 5, quadriplegia; and 6, death. Follow-up analyzes were performed blindly in mice treated with liposomes 
containing MOG peptide (PSMOG-liposomes, circles, n = 11), empty liposomes (PS-liposomes, squares, n = 10), peptide (MOG, 
rhombus, n = 8) or PBS (sham, triangles, n = 13). Results are mean ± standard error of the mean from two independent experiments. 
Significant differences were found when comparing PSMOG-liposomes group with PS-liposomes and sham groups (*p ≤ 0.05, 
nonparametric Mann–Whitney test). (B) Mean weight in experimental autoimmune encephalomyelitis-mice after treatment with 
liposomes containing MOG peptide (PSMOG-liposomes, circles, n = 11), empty liposomes (PS-liposomes, squares, n = 10), peptide 
(MOG, rhombus, n = 8) or PBS (sham, triangles, n = 13). Results are mean ± standard error of the mean from two independent 
experiments. Significant differences were found when comparing PSMOG-liposomes treated group with all control groups  
(***p < 0.001, nonparametric Mann–Whitney test). 
PSMOG-liposome: PS-rich liposome loaded with myelin-oligodendrocyte glycoprotein.
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± 3.48% (mean ± SD) and 14.69 ± 2.67%, respectively 
(p < 0.05). However, we noted that the percentage of 
CD25+ FoxP3- T cells in PSMOG-liposomes group 
increased when compared with their sham counter-
parts, that being of 14.83 ± 5.47% and 9.65 ± 2.84%, 
respectively (p < 0.05) (Figure 5A). Indeed, the percent-
age of CD25+ FoxP3- T cells in PSMOG-liposomes 
treated mice correlated inversely with the clinical score 
at day 15 p.i. (Spearman’s r = -0.9258, p < 0.0001), as 
shown in Figure 5B, but no correlation was observed 
between these parameters in sham group (data not 
shown). Nevertheless, the number of CD25+ Foxp3+ 
cells tended to decrease in PSMOG-liposomes group 
(6.31 × 105 ± 2.03 × 105), when compared with sham 
group (11.05 × 105 ± 0.76 × 105), although differences 
are not statistically significant. Regarding the absolute 
number of CD25+ FoxP3- T cells, similar results were 
obtained in PSMOG-liposomes treated group (9.13 × 
105 ± 4.58 × 105) and sham group (8.95 × 105 ± 1.71 
× 105). With these results, the expression of CD4+ Tr1 
cell markers CD49b and LAG-3 was next examined on 
the splenocytes of the sham and PSMOG-liposomes 
groups by analyzing their median of fluorescence 
intensity. Although there were no statistically signifi-
cant differences in the expression of CD49b between 
sham (90.18 ± 11.49, mean ± SD) and treated (95.12 ± 
13.84) groups, a tendency for this marker to increase 
in PSMOG-liposomes treated mice was observed 
(Figure 5C). Supporting this tendency, LAG-3 expres-
sion was significantly increased in PSMOG-liposomes 
treated mice (387.5 ± 88.53) when compared with 
sham group (304.6 ± 54.41) (p ≤ 0.05).
Discussion
It is well known that apoptotic cell clearance by 
phagocytes maintains immunological homeostasis and 
induces antigen-specific immune tolerance [22,23]. In 
fact, apoptotic mimicry is a strategy to induce toler-
ance, lost in autoimmune diseases. In this sense, sev-
eral approaches have been developed [7,20,24]. We have 
recently shown that apoptotic mimicry by means of 
liposomes – rich in PS and encapsulating autoanti-
gens – arrest autoimmunity in T1D [8]. Therefore, we 
hypothesized that by replacing the encapsulated auto-
antigen, PS-liposomes would show therapeutic effect 
for other autoimmune diseases.
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Figure 5. T cell subsets in mice treated with PS-rich liposomes loaded with myelin-oligodendrocyte glycoprotein. (A) Percentage 
of classical regulatory T cells (CD25+ FoxP3+ cells gated in CD4+ T cells) and CD25+ FoxP3- cells (gated in CD4+ T cells) in the spleen 
of PSMOG-liposomes treated mice (circles, n = 6) or sham control group (triangles, n = 12) at day 15 p.i. Lines show the mean of 
6–12 mice. Comparisons between groups showed significant differences (p < 0.05, nonparametric Mann–Whitney test). (B) Correlation 
between clinical score at day 15 p.i. and percentage of CD25+ FoxP3- cells (gated in CD4+ T cells) in PSMOG-liposomes treated mice 
(****p < 0.0001, Spearman’s correlation analysis). (C) Left panel: MFI of CD49b and LAG-3 membrane expression in CD4+ T cells 
from PSMOG-liposomes treated mice or sham control group at day 15 p.i. Lines show the mean of 6–12 mice. Comparisons between 
groups showed significant differences (p < 0.05, nonparametric Mann-Whitney test). Right panel: Histogram of one representative 
experiment is shown for CD49b and LAG3 expression in mice treated with PSMOG-liposomes (orange) or sham (blue). 
FMO: Fluorescence minus one; MFI: Median of fluorescence intensity; P.i.: Post immunization.
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We selected MS to assess therapeutic versatility of 
liposomes. In the present study, we have validated the 
efficacy of PS-liposomes in the experimental model 
of the disease. MS is one of the most frequent neuro-
logical disorders [25], and epidemiological studies have 
highlighted an increasing rate of prevalence of the dis-
ease. Prevention and cure of MS is not yet possible. 
Some therapies can slow the progress of the disease and 
manage the symptoms, but they cause important side 
effects.
The growing field of micro and nanotechnology 
has enabled new strategies for MS and other autoim-
mune diseases to be tested in experimental models. 
Nanoparticles and microparticles have been used to 
induce T-cell tolerance and as vehicles for anti-inflam-
matory drugs [26–29], and a few of them have reached 
the clinic [30]. The relevance of our results relies in 
the potential of PS-liposomes to develop a platform 
for the treatment of several autoimmune disorders, 
using a biomimicry strategy, based on a physiological 
process such as efferocytosis. In our knowledge, this 
is the first work in the context of EAE that confirms 
PS-liposomes as a powerful tool to encapsulate autoan-
tigens, co-delivering a double-signal of tolerance and 
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specificity to arrest autoimmune reactions in a syner-
gistic, effective and safe manner. Liposomes provide an 
effective tolerogenic-signal induction with additional 
advantages. They are biocompatible, completely bio-
degradable, nontoxic, nonimmunogenic, suitable for 
encapsulation of peptides with varying solubility and 
low cost [31]. Moreover, they protect the encapsulated 
drug from the external environment and exhibit flex-
ibility to be coupled with site-specific ligands (e.g., PS 
and its receptor in DCs).
Various types of liposomes are being used as vehi-
cles [32] for anticancer drugs, vaccines and anti-inflam-
matory agents [2,33,34]. In this sense, liposomes have 
been used for the treatment of MS but PS was not 
included in their composition [35]. PS is the main ‘eat 
me’ and ‘tolerate me’ signal of the apoptotic cell mem-
brane, which allows recognition and phagocytosis by 
antigen presenting cells such as DCs [36]. Apoptotic cell 
signaling prevents maturation of DCs and promotes 
autoantigen presentation in a tolerogenic manner, to 
induce specific tolerance rather than autoimmunity [7]. 
Conversely, a high rate of apoptosis and/or defects in 
their clearance contribute to autoimmunity, since apop-
totic cells turn into secondary necrotic cells, releasing 
proinflammatory signals that enable maturation of 
DCs and immunogenic presentation of autoantigens. 
In this sense, neuronal apoptosis is induced in cultures 
exposed to cerebrospinal fluid from MS patients [37], 
pointing to a relevant role of apoptosis in the disease 
progression. These data fit well with the herein reported 
effect of PSMOG-liposomes in the  re-establishment of 
self-tolerance in the EAE model.
The morphological and physicochemical features 
of the liposomes are key to provide them with this 
tolerogenic potential. To validate the liposome effect 
reported in experimental T1D in MS, we designed 
EAE-adapted liposomes to be similar to those used 
for T1D. In this work, we demonstrate the capacity of 
this already-published lipid composition to prevent a 
completely different autoimmune disease by replacing 
the relevant autoantigen in T1D with the correspond-
ing peptide for EAE and keeping lipid concentration, 
diameter and charge. This conceptual innovation 
allows us to consider this strategy as a potential plat-
form for the reestablishment of immunological toler-
ance. In vitro experiments demonstrate that liposomes 
are phagocytosed by DCs from another experimen-
tal model (EAE) inducing the same phenotypic and 
 functional changes in DCs than in the T1D model [8].
In vitro experiments revealed crucial immunological 
consequences of the capture of PSMOG-liposomes by 
iDCs. First, liposomes were rapidly, actively and safely 
captured through phagocytosis by DCs, as demon-
strated by co-culture experiments at 37 and 4°C [38,39]. 
Endocytic processes involve the internalization of 
large-sized particles or a large volume of the extracel-
lular bulk. These are termed phagocytosis and mac-
ropinocytosis, respectively: phagocytosis refers to the 
transport of large particles (>250 nm in diameter) by 
immune system specialized cells (macrophages, DCs 
and neutrophils), while pinocytosis refers to ingestion of 
fluids and solutes (about 100 nm in diameter) by mam-
malian cells [40]. In this sense, the large size of the here 
reported liposomes – diameter greater than 500 nm – 
and the presence of PS as an ‘eat-me’ signal promote 
active phagocytosis by DCs [8,41]. Second, after lipo-
some engulfment, DCs increased CD40 membrane 
expression and decreased CD86, and maintained low 
membrane expression of MHC class II expression, 
features of tolerogenic DCs. Interestingly, PSMOG-
liposomes uptake induced the secretion of PGE
2
, an 
essential mediator in the maintenance of tolerance 
after efferocytosis [42]. These results are in agreement 
with our previous study, using specific PS-liposomes 
for T1D.
Importantly, liposome treatment was successful at 
arresting autoimmunity in vivo and greatly amelio-
rating clinical symptoms in treated mice in terms of 
severity, incidence and disease onset. As expected, no 
effect was observed when mice received empty PS-
liposomes. As described from previous studies [43], 
treatment with MOG peptide resulted in an ameliora-
tion of the disease, and it was in an antigen-specific 
manner [44]. However, the effect of MOG peptide 
appeared to be minor than the induced by PSMOG-
liposomes, which reflect the joint action of both PS and 
MOG. Also, combined therapy with MOG peptide 
and other compounds such as vitamin D or Rapamy-
cin displays synergisms in ameliorating EAE [45,46]. 
Here we show the antigen specificity of the treatment, 
as empty PS-liposomes do not provide protection in 
front EAE symptoms whereas treatment with lipo-
somes filled with MOG peptide clearly resulted in a 
strong protection from disease. This immunotherapy 
is safe and even more biologically effective than the 
treatment with MOG peptide because PS-liposomes 
mimic apoptotic cells, thus providing specificity and 
tolerogenic signals to DCs. These results are consistent 
with previous data obtained in T1D studies, showing 
a requirement for β-cell autoantigens in liposomes to 
arrest  autoimmunity to islet cells [8].
The mechanism of action of the herein reported 
immunotherapy should be grounded on the promo-
tion of regulatory mechanisms by DCs after liposome 
capture. The decrease in frequency of CD25+ FoxP3+ 
CD4+ T cells as well as in absolute numbers (although 
nonstatistically significant) is consistent with an 
increase in frequency of CD25+ FoxP3- CD4+ T cells. 
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However, absolute numbers of CD25+ FoxP3- CD4+ 
T cells are not altered by liposomes, suggesting that 
additional regulatory mechanisms may be involved. 
These results are in line with those obtained in experi-
mental autoimmune T1D [8]. In fact, CD25+ FoxP3- 
CD4+ T-cell frequency is higher in treated mice with 
minor EAE clinical score, so it is reasonable to spec-
ulate that these cells have a regulatory function and 
can belong to a subset of antigen-specific regulatory 
T lympho cytes. For instance, we cannot rule out an 
increase in antigen-specific Tr1 cells after PSMOG-
liposomes treatment, based on the CD49b and LAG-3 
expression profile [21], as reported in other nano-
therapies aimed to restore self-tolerance [8,29]. LAG-3 
marker is significantly increased in mice treated with 
PSMOG-liposomes and, although statistically non-
significant, CD49b shows a tendency to increase in 
treated mice. In this sense, LAG-3 expression is suffi-
cient to confer regulatory activity in CD4+ T cells [47], 
upholding the possible generation of Tr1 with the 
described  immunotherapy.
Altogether our results highlight the potential of a 
PS-liposomes platform for the prevention and rever-
sion of autoimmune diseases, with advantages in terms 
of production feasibility, stability, safety, biocompati-
bility, costs and customization for different diseases, as 
long as the autoantigen is identified. The here reported 
work validates PS-liposomes as a powerful tool to 
encapsulate autoantigens, co-delivering a double- signal 
of tolerance and specificity to arrest autoimmunity in a 
synergistic and effective manner.
Conclusion
PS-liposomes encapsulating self-peptides are sphere-
shaped microvesicles designed to achieve tolerogenic 
delivery of autoantigens into antigen presenting 
cells in order to arrest autoimmunity. PS-liposomes 
loaded with a MS autoantigen (MOG) were prepared 
and tested in an experimental model of the disease, 
the EAE-mouse model. PSMOG-liposomes were 
efficiently captured by DCs, inducing a tolerogenic 
phenotype, and ceasing the autoimmune reaction 
in EAE-mice, in the same way that PS-liposomes 
customized for T1D do. This work validates PS-
liposomes as a powerful tool for the re-establish-
ment of tolerance and for the treatment of different 
 autoimmune  diseases.
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Background
•	 The prevalence of autoimmunity is on the rise, and there is no cure for any autoimmune disease, caused by the 
loss of tolerance to self.
•	 One of the mechanisms to maintain self-tolerance is the efficient removal of apoptotic cells. For this reason, a 
liposome-based antigen-specific immunotherapy was generated.
•	 Liposomes that mimic apoptotic β cells prevent Type 1 diabetes through specific and definitive  
re-establishment of tolerance.
Aim
•	 Having proved that liposomes rich in phosphatidylserine (PS) and loaded with autoantigens were effective for 
Type 1 diabetes, our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis.
Results
•	 PS-Liposomes loaded with a multiple sclerosis autoantigen are efficiently phagocytosed by dendritic cells and 
induce tolerogenic features in dendritic cells.
•	 After post immunization administration, MOG-loaded PS-liposomes reduce the incidence and severity of 
experimental autoimmune encephalomyelitis, and delay the onset.
•	 The arrest of the autoimmune attack correlates with an increase in the CD25+ FoxP3- CD4+ T-cell subset.
Conclusion
•	 This is the first work in the context of experimental autoimmune encephalomyelitis that confirms PS-
liposomes as a powerful tool to encapsulate autoantigens, co-delivering a double-signal of tolerance and 
specificity to arrest autoimmunity in a synergistic, effective and safe manner. Autoantigen-loaded PS-
liposomes are candidates for immunotherapy to induce self-tolerance, with high potential to operate as a 
platform for autoimmune diseases.
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